Compare NBIX & SMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | SMTC |
|---|---|---|
| Founded | 1992 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5B | 17.3B |
| IPO Year | 1996 | 2003 |
| Metric | NBIX | SMTC |
|---|---|---|
| Price | $141.13 | $187.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 28 | 16 |
| Target Price | $207.81 | ★ $208.67 |
| AVG Volume (30 Days) | 1.2M | ★ 3.1M |
| Earning Date | 10-27-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.95 | ★ 79.65 |
| EPS | ★ 3.30 | 0.27 |
| Revenue | $161,626,000.00 | ★ $1,049,975,000.00 |
| Revenue This Year | $36.49 | $41.57 |
| Revenue Next Year | $16.51 | $29.63 |
| P/E Ratio | ★ $42.64 | $691.07 |
| Revenue Growth | ★ 977.51 | 15.47 |
| 52 Week Low | $122.14 | $60.28 |
| 52 Week High | $186.12 | $190.64 |
| Indicator | NBIX | SMTC |
|---|---|---|
| Relative Strength Index (RSI) | 38.83 | 60.14 |
| Support Level | $125.18 | $145.69 |
| Resistance Level | $142.82 | $190.64 |
| Average True Range (ATR) | 3.63 | 9.73 |
| MACD | -0.24 | 0.13 |
| Stochastic Oscillator | 27.51 | 74.71 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Semtech Corp is a provider of high-performance semiconductors powering data center networking, Internet of Things ("IoT") connectivity, and cellular infrastructure solutions. The company designs, develops, manufactures, and markets a diverse portfolio of products for commercial applications, addressing the infrastructure, high-end consumer, and industrial end markets. The company operates in four reportable segments: Signal Integrity, Analog Mixed Signal and Wireless, IoT Systems, and Connected Services. The majority of the company's revenue is earned through the Analog Mixed Signal and Wireless segment. Geographically, the majority of the company's revenue is earned from the Asia Pacific region; the company also operates in North America and Europe.